| Outcome Measures: |
Primary: Glucagon receptor occupancy, Change of glucagon receptor tracer binding in the liver with SAR425899 between Day 1 and Day 20, Day 1 and Day 20 | Secondary: GLP-1 receptor occupancy, Change of GLP-1 receptor tracer binding in the pancreas with SAR425899 between Day 1 and Day 17, Day 1 and Day 17|Adverse events, Number of adverse events in patients under treatment with SAR425899, Up to 27 days|Pharmacokinetics, Assessment of SAR425899 maximum plasma concentration (Cmax), Day 20|Change in fasting plasma glucose (FPG), Absolute change in FPG from baseline to Day 20, Day 1 to Day 20|Change in ketone bodies, Absolute change in ketone bodies from baseline to Day 20, Day 1 to Day 20|Change lipid biomarkers, Absolute change cholesterol from baseline to Day 20, Day 1 to Day 20|Change in volume of distribution (Vt) in the liver, Change of glucagon receptor tracer Vt in the liver with SAR425899 between Day 1 and Day 20, Day 1 and Day 20|Change in Vt in the pancreas, Change of GLP-1 receptor tracer Vt in the pancreas with SAR425899 between Day 1 and Day 17, Day 1 and Day 17|Average standard uptake values (SUVs) of PET tracers in the liver and pancreas, Average SUVs for glucagon and GLP-1 tracer in liver and pancreas, Day 1, Day 17 and Day 20|Pharmacokinetics, Assessment of SAR425899 time to reach Cmax ( tmax), Day 20|Pharmacokinetics, Assessment of SAR425899 area under the concentration versus time curve (AUC), Day 20|Pharmacokinetics, Assessment of SAR425899 terminal elimination half-life ( t1/2), Day 20|Pharmacokinetics, Assessment of SAR425899 total body clearance from the plasma (CL), Day 20|Change lipid biomarkers, Absolute change in free fatty acids from baseline to Day 20, Day 1 to Day 20|Change lipid biomarkers, Absolute change in triglycerides from baseline to Day 20, Day 1 to Day 20
|
